FLT3LG and melanoma: Similarly, in mice bearing subcutaneous B16 melanomas and in the transgenic Tyr : CreER BrafCAPtenloxPCtnnb1lox-ex3 mouse model where melanoma is induced with a cutaneous application of 4-hydroxytamoxifen, Flt3L treatment expanded pre-DCs and DCs both in the bone marrow and systemically, and resulted in enhanced antitumor immunity and delayed tumor growth in synergy with anti-PD-L1 and poly(I:C) immunotherapy (163).